Drug discovery: From hits to clinical candidates

The Third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CNS Disorders

Volumn , Issue , 2008, Pages 103-166

  Celanire, Sylvain ^a   Lebon, Florence ^a   Stark, Holger ^b  

^a Global Chemistry UCB   (Belgium)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883705157     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (304)

1. Aslanian, R. and Shih, N.Y. 2004. Recent progress in histamine H3 receptor chemistry. Ann. Rep. Med. Chem. 39: 57-66.
2. Stark, H., Kathmann, M., Schlicker, E. et al. 2004. Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists. Mini-Rev. Med. Chem. 4: 965-977.
3. De Esch, I.J.P. and Belzar, K.J. 2004. Histamine H3 receptor agonists. Mini-Rev. Med. Chem. 4: 955-963.
4. Cowart, M., Altenbach, R., Black, L. et al. 2004. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists. Mini-Rev. Med. Chem. 4: 979-992.
5. Leurs, R., Bakker, R.A., Timmerman, H. et al. 2005. The histamine H3 receptor: From gene cloning to H3 receptor drugs. Nat. Rev. Drug Disc. 4: 107-120.
6. Celanire, S., Wijtmans, M., Talaga, P. et al. 2005. Keynote review: Histamine H3 receptor antagonists reach out for the clinic. Drug Disc. Today 10: 1613-1627.
7. Letavic, M.A., Barbier, A.J., Dvorak, C.A. et al. 2006. Recent medicinal chemistry of the histamine H3 receptor. Prog. Med. Chem. 44: 181-206.
8. IDdb3. 2007. Investigational Drugs Database (IDdb). Thomson Current Drugs. Thomson Scientific. http://www. iddb3.com.
9. Derwent Discovery World Drug Alert Plus 2007. Thomson Scientific. https://www. derwent-discovery.com/.
10. Lovenberg, T.W., Pyati, J., Chang, H. et al. 2000. Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther. 293: 771-778.
11. Berlin, M. and Boyce, C.W. 2007. Recent advances in the development of histamine H3 antagonists. Expert Opin. Ther. Pat. 17: 675-687.
12. Dale, H. and Laidlaw, P. 1910. The physiological action of beta-iminazolylethylamine. J. Physiol. 41: 318-344.
13. De Luca, L. 2006. Naturally occurring and synthetic imidazoles: Their chemistry and their biological activities. Curr. Med. Chem. 13: 1-23.
14. Boehlow, T.R., Harburn, J.J., and Spilling, C.D. 2001. Approaches to the synthesis of some tyrosine-derived marine sponge metabolites: Synthesis of verongamine and purealidin N. J. Org. Chem. 66: 3111-3118.
15. Chen, Z., Sakurai, E., Hu, W. et al. 2004. Pharmacological effects of carcinine on histaminergic neurons in the brain. Br. J. Pharmacol. 143: 573-580.
16. Tanida, M., Niijima, A., Fukuda, Y. et al. 2005. Dose-dependent effects of l-carnosine on the renal sympathetic nerve and blood pressure in urethane-anesthetized rats. Am. J. Physiol. 288: R447-R455.
17. Shen, Y., Hu, W.W., Fan, Y.Y. et al. 2007. Carnosine protects against NMDA-induced neurotoxicity in differentiated rat PC12 cells through carnosine-histidine-histamine pathway and H1/H3 receptors. Biochem. Pharmacol. 73: 709-717.
18. Nagai, K., Niijima, A., Yamano, T. et al. 2003. Possible role of l-carnosine in the regulation of blood glucose through controlling autonomic nerves. Exp. Biol. Med. 228: 1138-1145.
19. Babizhayev, M., Seguin, M., Gueyene, J. et al. 1994. l-Carnosine (β-alanyl-l-histidine) and carcinine (β-alanylhistamine) act as natural antioxidants with hydroxyl-radicalscavenging and lipid-peroxidase activities. Biochemistry 304: 509-516.
20. Pompni, S.A. and Gullo, V.P. 1994. US5352707A.
21. Swanson, D.M., Wilson, S.J., Boggs, J.D. et al. 2006. Aplysamine-1 and related analogs as histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 16: 897-900.
22. Zhao, C., Bennani, Y.L., Gopalakrishnan, S. et al. 2005. Discovery of novel natural alkaloid conessine as potent histamine H3 receptor antagonist, 230th ACS National Meeting, Washington, DC, August 28 to September 1, 2005. Abst. MEDI-104.
23. Zhao, C., Sun, M., Cowart, M.D. et al. 2005. WO2005100377A1.
24. Zhao, C., Sun, M., Cowart, M.D. et al. 2005. US2005227953A1.
25. Kopach, M.E., Fray, A.H., and Meyers, A.I. 1996. An asymmetric route to the conanine BCDE ring system. A formal total synthesis of (+)-conessine. J. Am. Chem. Soc. 118: 9876-9883.
26. Jiang, B. and Xu, M. 2004. Highly enantioselective construction of fused pyrrolidine systems that contain a quarternary stereocenter: Concise formal synthesis of (+)-conessine. Angew. Chem. Int. Ed. 43: 2543-2546.
27. Anderson, N. and Borlak, J. 2006. Drug-induced phospholipidosis. FEBS Lett. 580: 5533-5540.
28. Reasor, M.J. and Kacew, S. 2001. Drug-induced phospholipidosis: Are there functional consequences. Exp. Biol. Med. 226: 825-830.
29. Zirihi, G.N., Grellier, P., Guede-Guina, F. et al. 2005. Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. Bioorg. Med. Chem. Lett. 15: 2637-2640.
30. Newman, D.J., Cragg, C.G., and Snader, K.M. 2003. Natural products as source of new drugs over the period 1981-2002. J. Nat. Prod. 66: 1022-1037.
31. Arrang, J.M., Garbarg, M., and Schwartz, J.C. 1983. Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302: 832-837.
32. Lim, H.D., van Rijn, R.M., Ling, P. et al. 2005. Evaluation of histamine H1-, H2-, and H3- re ceptor ligands at the human histamine H4 receptor: Identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. 314: 1310-1321.
33. Gbahou, F., Vincent, L., Humbert-Claude, M. et al. 2006. Compared pharmacology of human histamine H3 and H4 receptors: Structure-activity relationships of histamine derivatives. Br. J. Pharmacol. 147: 744-754.
34. Kitbunnadaj, R., Zuiderveld, O.P., De Esch, I.J.P. et al. 2003. Synthesis and structure- activity relationships of conformationally constrained histamine H3 receptor agonists. J. Med. Chem. 46: 5445-5457.
35. Harusawa, S., Araki, L., Imazu, T. et al. 2003. Synthesis of (+-)-trans- or cis-(5-amino methyltetrahydrofuranyl)imidazole by Mitsunobu cyclization: Synthetic studies toward novel histamine H3 or H4-ligands. Chem. Pharm. Bull. 51: 325-329.
36. Kitbunnadaj, R., Hashimoto, T., Poli, E. et al. 2005. N-Substituted piperidinyl alkyl imidazoles: Discovery of methimepip as a potent and selective histamine H3 receptor agonist. J. Med. Chem. 48: 2100-2107.
37. Kitbunnadaj, R., Hoffmann, M., Fratantoni, S.A. et al. 2005. New high affinity H3 receptor agonists without a basic side chain. Bioorg. Med. Chem. 13: 6309-6323.
38. Kazuta, Y., Hirano, K., Natsume, K. et al. 2003. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-Aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure. J. Med. Chem. 46: 1980-1988.
39. Kitbunnadaj, R., Zuiderveld, O.P., Christophe, B. et al. 2004. Identification of 4-(1HImidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H3 receptor agonist. J. Med. Chem. 47: 2414-2417.
40. Celanire, S., Gillard, M., Christophe, B. et al. 2007. Pharmacological characterization, in vitro and in vivo ADME properties of immethridine, a potent and highly selective histamine H3R agonist. 35th Eur. Histamine Res. Soc. Delphi, Greece, Abst. P5.
41. Govoni, M., Lim, H.D., El Atmioui, D. et al. 2006. A chemical switch for the modulation of the functional activity of higher homologues of histamine on the human histamine H3 receptor: Effect of various substitutions at the primary amino function. J. Med. Chem. 49: 2549-2557.
42. Krause, M., Stark, H., Schunack, W. 2001. Azomethine prodrugs of (R)-a-methylhistamine, a highly potent and selective histamine H3-receptor agonist. Curr. Med. Chem. 8: 1329-1340.
43. Fozard, J.R. 2000. BP-294 (Ste Civile Bioprojet). Curr. Opin. Investig. Drugs 1: 86-89.
44. Stark, H., Krause, M., Rouleau, A. et al. 2001. Enzyme-catalyzed prodrug approaches for the histamine H3-receptor agonist (R)-a-methylhistamine. Bioorg. Med. Chem. Lett. 9: 191-198.
45. Sasse, A., Ligneau, X., Rouleau, A. et al. 2002. Influence of bulky substituents on histamine H3 receptor agonist/antagonist properties. J. Med. Chem. 45: 4000-4010.
46. Pelloux-Leon, N., Fkyerat, A., Piripitsi, A. et al. 2004. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain. J. Med. Chem. 47: 3264-3274.
47. Meier, G., Krause, M., Huels, A. et al. 2004. 4-(w-(Alkyloxy)alkyl)-1H-imidazole derivatives as histamine H3 receptor antagonists/agonists. J. Med. Chem. 47: 2678-2687.
48. Tedford, C.E., Hoffmann, M., Seyedi, N. et al. 1998. High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. Eur. J. Pharmacol. 351: 307-311.
49. Liu, H., Kerdesky, F.A., Black, L.A. et al. 2004. An efficient multigram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration. J. Org. Chem. 69: 192-194.
50. Ito, S., Yoshimoto, R., Miyamoto, Y. et al. 2006. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor. Eur. J. Pharmacol. 529: 40-46.
51. Morisset, S., Rouleau, A., Lineau, X. et al. 2000. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408: 860-864.
52. Gbahou, F., Rouleau, A., Morisset, S. et al. 2003. Protean agonism at histamine H3 receptors in vitro and in vivo. Proc. Natl Acad. Sci. U.S.A. 100: 11086-11091.
53. Kenakin, T. 2001. Inverse, protean, and ligand-selective agonism: Matters of receptor conformation. FASEB J. 15: 598-611.
54. Stark, H. 2004. Turning from monogamy to strategic promiscuity. Drug Disc. Today 9: 736-737.
55. De Esch, I.J.P., Thurmond, R.L., Jongejan, A. et al. 2005. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol. Sci. 26: 462-469.
56. Zhang, M., Ballard, M.E., Pan, L. et al. 2005. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res. 1045: 142-149.
57. Yang, R., Hey, J.A., Aslanian, R. et al. 2002. Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 66: 128-135.
58. Watanabe, M., Kazuta, Y., Hayashi, H. et al. 2006. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure. J. Med. Chem. 49: 5587-5596.
59. Vaccaro, W.D., Sher, R., Berlin, M. et al. 2006. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg. Med. Chem. Lett. 16: 395-399.
60. Berlin, M., Ting, P.C., Vaccaro, W.D. et al. 2006. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 16: 989-994.
61. Rivara, M., Vacondio, F., Silva, C. et al. 2008. Synthesis and stability in biological of 1Himidazole-1-carboxylates of RS203, an antagonist of the histamine H3 receptor. Chem. Biodivers. 5: 140-152.
62. Lin, J.H. and Lu, A.Y. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35: 361-390.
63. Pillot, C., Ortiz, J., Heron, A. et al. 2002. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neuroscience 22: 7272-7280.
64. Kalindjian, S.B., Buck, I.M., Linney, I.D. et al. 1999. WO9942458A1.
65. Schwartz, J-C., Arrang, J-M., Garbarg, M. et al. 2000. EP978512A1.
66. Schwartz, J. and Lecomte, J. 2006. WO2006103546A2.
67. Schwartz, J. and Lecomte, J. 2006. WO2006103537A2.
68. Bertrand, I., Capet, M., Lecomte, J-M. et al. 2006. WO2006117611A1.
69. Bertrand, I., Capet, M., Lecomte, J-M. et al. 2006. WO2006117609A2.
70. Meier, G., Apelt, J., Reichert, U. et al. 2001. Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur. J. Pharm. Sci. 13: 249-259.
71. Ligneau, X., Landais, L., Perrin, D. et al. 2007. Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem. Pharmacol. 73: 1215-1224.
72. Ligneau, X., Perrin, D., Landais, L. et al. 2007. BF2.649 [1-{3-[3-(4-chlorophenyl)pro poxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J. Pharmacol. Exp. Ther. 320: 365-375.
73. Lazewska, D., Kiec-Kononowicz, K., Elz, S. et al. 2005. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: The alkyl derivatives. Pharmazie 60: 403-410.
74. Lazewska, D., Ligneau, X., Schwartz, J.C. et al. 2006. Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists. Bioorg. Med. Chem. 14: 3522-3529.
75. Miko, T., Ligneau, X., Pertz, H.H. et al. 2003. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(Phenoxymethyl)benzyl)piperidines and related compounds. J. Med. Chem. 46: 1523-1530.
76. Miko, T., Ligneau, X., Pertz, H.H. et al. 2004. Structural variations of 1-(4-(phenoxymethyl) benzyl)piperidines as nonimidazole histamine H3 receptor antagonists. Bioorg. Med. Chem. 12: 2727-2736.
77. Bertoni, S., Flammini, L., Manenti, V. et al. 2007. In vitro pharmacology at human histamine H3 receptors and brain access of non-imidazole alkylpiperidine derivatives. Pharmacol. Res. 55: 111-116.
78. A safety and effectiveness study of a single dose of JNJ-17216498 in patients with narcolepsy, http://clinicaltrials.gov/show/NCT00424931.
79. Bonaventure, P., Letavic, M., Dugovic, C. et al. 2007. Histamine H3 receptor antagonists: From target identification to drug leads. Biochem. Pharmacol. 73: 1084-1096.
80. Sanfilippo, P.J., Urbanski, M., Press, J.B. et al. 1988. Synthesis of (aryloxy)alkylamines. 2. Novel imidazo-fused heterocycles with calcium channel blocking and local anesthetic activity. J. Med. Chem. 31: 2221-2227.
81. Shah, C., McAtee, L., Breitenbucher, J.G. et al. 2002. Novel human histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 12: 3309-3312.
82. Chai, W., Breitenbucher, J.G., Kwok, A. et al. 2003. Non-imidazole heterocyclic histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 13: 1767-1770.
83. Apodaca, R., Carruthers, N.I., Carson, J.R. et al. 2002. WO2002024695A2.
84. Apodaca, R., Carruthers, N.I., Dvorak, C.A. et al. 2002. WO200212214A2.
85. Apodaca, R., Dvorak, C.A., Xiao, W. et al. 2003. A new class of diamine-based human histamine H3 receptor antagonists: 4-(Aminoalkoxy)benzylamines. J. Med. Chem. 46: 3938-3944.
86. Apodaca, R.L., Dvorak, C.A., Shah, C.R. et al. 2004. WO2004037257A1.
87. Airaksinen, A.J., Jablonowski, J.A., van der Mey, M. et al. 2006. Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1- ynyl)-[11C]benzyl]-morpholine: Evaluation of a potential PET ligand. Nucl. Med. Biol. 33: 801-810.
88. Carruthers, N.I., Shah, C.R., Swanson, D.M. et al. 2005. US2005222151A1.
89. Apodaca, R., Xiao, W., Jablonoski, J.A. et al. 2003. WO2003050099A1.
90. Dvorak, C.A., Apodaca, R., Barbier, A.J. et al. 2005. 4-phenoxypiperidines: Potent, conformationally restricted, non-imidazole histamine H3 antagonists. J. Med. Chem. 48: 2229-2238.
91. Apodaca, R., Carruthers, N.I., Dvorak, C.A. et al. 2002. WO200212190A2.
92. Apodaca, R.L., Jablonowski, J.A., Ly, K.S. et al. 2004. WO2004037801A1.
93. Carruthers, N.I., Shah, C.R., Swanson, D.M. et al. 2005. US2005222129A1.
94. Allison, B.D., Carruthers, N.I., Grice, C.A. et al. 2007. US2007066821A1.
95. Bogenstaetter, M., Carruthers, N.I. and Jablonowski, J.A. 2002. WO2002079168A1.
96. Mani, N.S., Jablonowski, J.A., and Jones, T.K. 2004. A scalable synthesis of a histamine H3 receptor antagonist. J. Org. Chem. 69: 8115-8117.
97. Hancock, A.A. 2006. The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem. Pharmacol. 71: 1103-1113.
98. Esbenshade, T.A., Fox, G.B., and Cowart, M.D. 2006. Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Mol. Interv. 6: 77-88, 59.
99. Bennani, Y. 2005. Selective tissue targeting as a strategy for CNS drugs: Application to H3 blockers. Interplay of Chemistry and Biology in Integrative Drug Discovery meeting, Miami, FL, March.
100. Faghih, R., Dwight, W., Gentles, R. et al. 2002. Structure-activity relationships of nonimidazole H(3) receptor ligands. Part 1. Bioorg. Med. Chem. Lett. 12: 2031-2034.
101. Faghih, R., Dwight, W., Black, L. et al. 2002. Structure-activity relationships of nonimidazole H3 receptor ligands. Part 2: Binding preference for d-amino acids motifs. Bioorg. Med. Chem. Lett. 12: 2035-2037.
102. Esbenshade, T.A., Krueger, K.M., Miller, T.R. et al. 2003. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 305: 887-896.
103. Fox, G.B., Pan, J.B., Radek, R.J. et al. 2003. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. 305: 897-908.
104. Vasudevan, A., Conner, S.E., Gentles, R.G. et al. 2002. Synthesis and evaluation of potent pyrrolidine H3 antagonists. Bioorg. Med. Chem. Lett. 12: 3055-3058.
105. Bennani, Y.L., Faghih, R., Dwight, W.J. et al. 2002. WO200206223A1.
106. Gfesser, G.A., Zhang, H., Dinges, J. et al. 2004. Structure-activity relationships of non-imidazole H3 receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists. Bioorg. Med. Chem. Lett. 14: 673-676.
107. Gfesser, G.A., Faghih, R., Bennani, Y.L. et al. 2005. Structure-activity relationships of arylbenzofuran H3 receptor antagonists. Bioorg. Med. Chem. Lett. 15: 2559-2563.
108. Curtis, M.P., Dwight, W., Pratt, J. et al. 2004. D-amino acid homopiperazine amides: Discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist. Arch. Pharm. 337: 219-229.
109. Bennani, Y.L., Black, L.A., Dwight, W.J. et al. 2001. US2001049367A1.
110. Hancock, A.A., Bush, E.N., Jacobson, P.B. et al. 2004. Histamine H3 antagonists in models of obesity. Inflamm. Res. 53: S47-S48.
111. Hancock, A.A., Bennani, Y.L., Bush, E.N. et al. 2004. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur. J. Pharmacol. 487: 183-197.
112. Hancock, A.A., Diehl, M.S., Fey, T.A. et al. 2005. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy. Inflamm. Res. 54: S27-S29.
113. Hancock, A.A. and Brune, M.E. 2005. Assessment of pharmacology and potential antiobesity properties of H3 receptor antagonists/inverse agonists. Expert Opin. Invest. Drugs 14: 223-241.
114. Hancock, A.A., Bitner, R.S., Krueger, K.M. et al. 2006. Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflamm. Res. 55: S42-S44.
115. Hancock, A.A., Diehl, M.S., Faghih, R. et al. 2004. In vitro optimization of structure activity relationships of analogs of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. Basic Clin. Pharmacol. Tox. 95: 144-152.
116. Fey, T.A., Bush, E.A., Dickinson, R.A. et al. 2004. Effects of A-423579, a novel histamine-3 receptor antagonist in rodent models of diet-induced obesity. Experimental Biology, Washington, DC, April 17-21. Abst. #394.5.
117. Bennani, Y.L. and Faghih, R. 2002. WO200240461A2.
118. Faghih, R., Dwight, W., Pan, J.B. et al. 2003. Synthesis and SAR of aminoalkoxybiaryl-4-carboxamides: Novel and selective histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 13: 1325-1328.
119. Esbenshade, T.A., Fox, G.B., Krueger, K.M. et al. 2004. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem. Pharmacol. 68: 933-945.
120. Cowart, M., Faghih, R., Gfesser, G. et al. 2004. The medicinal chemistry of novel H(3) antagonists. Inflamm. Res. 53(Suppl 1): S69-S70.
121. Cowart, M., Pratt, J.K., Stewart, A.O. et al. 2004. A new class of potent non-imidazole H3 antagonists: 2-Aminoethylbenzofurans. Bioorg. Med. Chem. Lett. 14: 689-693.
122. Cowart, M., Faghih, R., Curtis, M.P. et al. 2005. 4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. 48: 38-55.
123. Miller, T.R., Krueger, K.M., Baranowski, J.L. et al. 2004. Pharmacological properties of novel, non-imidazole benzofuran H3 receptor antagonists. Experimental Biology, Washington, DC, April 17-21. Abst. #396.3.
124. Pu, Y.M., Grieme, T., Gupta, A. et al. 2005. A facile and scaleable synthesis of ABT-239, a benzofuranoid H3 antagonist. Org. Proc. Res. Dev. 9: 45-50.
125. Ku, Y.Y., Pu, Y.M., Grieme, T. et al. 2006. An efficient and convergent synthesis of the potent and selective H3 antagonist ABT-239. Tetrahedron 62: 4584-4589.
126. Esbenshade, T.A., Fox, G.B., Krueger, K.M. et al. 2005. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J. Pharmacol. Exp. Ther. 313: 165-175.
127. Fox, G.B., Esbenshade, T.A., Pan, J.B. et al. 2005. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 313: 176-190.
128. Esbenshade, T.A., Wetter, J., Marsh, K. et al. 2005. ABT-239, a potent human histamine H3 receptor antagonist with favorable drug-like properties. Experimental Biol., San Diego, CA, March 31 to April 5. Abst. #321.7.
129. Milicic, I., Krueger, K., Miller, T. et al. 2005. Pharmacological properties of the S-enantiomer of the histamine H3 receptor antagonist ABT-239: An inverse agonist with no anti-obesity effects. Experimental Biol., San Diego, CA, March 31 to April 5. Abst. #85.9.
130. Preusser, L.C., Fryer, R.M., Esbenshade, T.A. et al. 2005. ABT-239, a novel H3 receptor antagonist: Demonstration of a benign cardiovascular profile in the anesthetized canine. Experimental Biol., San Diego, CA, March 31 to April 5. Abst. #87.14.
131. Esbenshade, T.A. 2006. Preclinical pursuit of enhanced safety of H3 antagonists/inverse agonists for neuropsychiatric disease. The Histamine H3 Receptor: Clinical Applications of Antagonist/Inverse Agonists. 25th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum. Chicago, IL, July 7-13.
132. Cowart, M., Gfesser, G.A., Browman, K.E. et al. 2007. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: In vitro properties, drug-likeness, and behavioral activity. Biochem. Pharmacol. 73: 1243-1255.
133. Cowart, M., Faghih, R., Gfesser, G. et al. 2005. Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists. Inflamm. Res. 54: S25-S26.
134. Sun, M., Zhao, C., Gfesser, G.A. et al. 2005. Synthesis and SAR of 5-amino- and 5-(Aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency. J. Med. Chem. 48: 6482-6490.
135. Cowart, M.D., Sun, M., Altenbach, R.A. et al. 2005. Bicyclic heteroaromatic histamine H3 antagonists: Synthesis, potency, and in vivo profiles of analogs optimized for druglikeness. XIII RSC-SCI Med. Chem. Symp. September 22, Cambridge, U.K.
136. Altenbach, R.J., Black, L.A., Chang, S-J. et al. 2005. US2005256309A1.
137. Cowart, M.D., Ku, Y., Chang, S-J. et al. 2004. WO2004101559A1.
138. Altenbach, R.J., Black, L.A., Chang, S-J., et al. 2005. US2005256118A1.
139. Liu, H., Altenbach, R.J., Miller, T.R. et al. 2005. Design, synthesis, and structureactivity relationship of novel non-imidazole histamine H3 antagonists. 230th ACS National Meeting, Washington, DC, August 28 to September 1. Abst. MEDI-103.
140. Black, L.A., Nersesian, D.L., Sharma, P. et al. 2007. 4-[6-(2-Aminoethyl)naphthalen-2- yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration. Bioorg. Med. Chem. Lett. 17: 1443-1446.
141. Cowart, M., Black, L., Liu, H. et al. 2007. Optimization of H3 antagonist series for H3 selectivity over the hERG channel. 36th European Histamine Research Soceity Meeting, Florence, Italy, May 9-13. Abst. O35.
142. Altenbach, R.J., Liu, H., Esbenshade, T.A. et al. 2005. Bicyclic heteroaromatic histamine H3 antagonists: Synthesis, potency, and in vivo profiles of analogs optimized for drug-likeness. 230th ACS National Meeting, Washington, DC, August 28 to September 1. Abst. MEDI-102.
143. Milicic, I., Browman, K.E., Baranowski, J.L. et al. 2007. Effects of repeated H3 receptor antagonist administration on H3 receptor expression and function in rats. FASEB J. 21: A790-A79c.
144. Medhurst, A.D. 2004. Pre-clinical evaluation of novel H3 receptor antagonists. 33th Eur. Histamine Res. Soc. Meeting, April 28 to May 2, Düsseldorf/Köln, Germany. Abst. O2.
145. GlaxoSmithkline website, 2007, http://www.gsk.com/investors/pp_pipeline_standard.htm.
146. Wilson, D.M. 2005. Discovery of a novel series of potent, orally active histamine H3 receptor antagonists. Recent Disclosures of Clinical Drug Candidates; Society for Medicines Research Symposium, London, U.K., December 8.
147. Heightman, T.D. 2005. Knowledge-based high throughput lead generation. 13th RSCSCI Medicinal Chemistry Symposium, Cambridge, U.K., September 22.
148. Jin, J., Dhanak, D., Knight, S.D. et al. 2005. Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. Bioorg. Med. Chem. Lett. 15: 3229-3232.
149. Wilson, D.M. 2005. The discovery of a novel series of potent, orally active histamine H3 receptor antagonists. 13th RSC-SCI Medicinal Chemistry Symposium, Cambridge, U.K., September 22. delimi.
150. Dean, D., Apps, J., and Bamford, M. 2006. A novel series of histamine H3 antagonists. The 19th International Symposium in Medicinal Chemistry (Part IV), Istanbul, Turkey. Abst. P247.
151. Bamford, M.J., Dean, D.K., Sehmi, S.S. et al. 2004. WO2004056369A1.
152. Medhurst, A.D., Atkins, A.R., Beresford, I.J. et al. 2007. GSK189254-a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321: 1032-1045.
153. Woolley, M., Gartlon, J., and Pemberton, D. 2006. The histamine H3 receptor antagonist GSK189254, improves performance in the rat novel object recognition and attentional set shifting tasks. BAP Summer Meeting, 23-26 July, Oxford, U.K. Abst. TE12.
154. Giannoni, P., Passani, M.B., Nosi, D. et al. 2007. Detection of functional heterogeneity of histaminergic neurons in response to GSK189254, a novel H3 receptor antagonist. 36th Eur. Histamine. Res. Soc. Meeting, May 9-12, 2007, Florence, Italy. Abst. O6.
155. Medhurst, A.D., Briggs, M.A., Bruton, G. et al. 2007. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem. Pharmacol. 73: 1182-1194.
156. Bamford, M.J., Heightman, T.D., Wilson, D.M. et al. 2005. WO2005087746A1.
157. Bailey, N., Bamford, M.J., Dean, D.K. et al. 2005. WO2005058837A1.
158. Bamford, M.J. and Wilson, D.M. 2007. WO2007025596A1.
159. Orlek, B.S. 2006. Discovery of two new series of histamine H3 receptor antagonists. 17th Symposium on Medicinal Chemistry in Eastern England, Hatfield, U.K.
160. Johnstone, V. 2006. Design and synthesis of novel histamine H3 antagonists: Potential therapeutics for the treament of alzheimers disease. The 19th International Symposium in Medicinal Chemistry (Part IV). Istanbul, Turkey. Abst. P288.
161. Orlek, B.S. 2006. Discovery of two new series of histamine H3 receptor antagonists. Abstr. 17th Symposium on Medicinal Chemistry in Eastern England, Hatfield, U.K.
162. Cooper, I.R., Abberley, L., and Briggs, M. 2006. Novel potent H3 antagonists: Therapeutics for the treatment of dementia including alzheimer’s disease. The 19th International Symposium in Medicinal Chemistry (Part IV). Istanbul, Turkey. Abst. P247.
163. Bailey, J.M., Bruton, G., Huxley, A. et al. 2005. WO2005014571A1.
164. Ancliff, R.A., Bamford, M.J., Hodgson, S.T. et al. 2007. WO2007009741A1.
165. Zaragoza, F., Stephensen, H., Knudsen, S.M. et al. 2004. 1-Alkyl-4-acylpiperazines as a new class of imidazole-free histamine H3 receptor antagonists. J. Med. Chem. 47: 2833-2838.
166. Peschke, B., Bak, S., Hohlweg, R. et al. 2004. Cinnamic amides of (S)-2-(aminomethyl) pyrrolidines are potent H3 antagonists. Bioorg. Med. Chem. 12: 2603-2616.
167. Peschke, B., Bak, S., Hohlweg, R. et al. 2006. Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor. Bioorg. Med. Chem. Lett. 16: 3162-3165.
168. Lau, J.F., Jeppesen, C.B., Rimvall, K. et al. 2006. Ureas with histamine H3-antagonist receptor activity-A new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. 16: 5303-5308.
169. Zaragoza, F., Stephensen, H., Peschke, B. et al. 2005. 2-(4-Alkyl-1-piperazinyl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J. Med. Chem. 48: 306-311.
170. Jesudason, C.D., Beavers, L.S., Cramer, J.W. et al. 2006. Synthesis and SAR of novel histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. 16: 3415-3418.
171. Beavers, L.S., Gadski, R.A., Hipskind, P.A. et al. 2002. WO2002076925A2.
172. Beavers, L.S., Gadski, R.A., Hipskind, P.A. et al. 2005. WO2005082893A2.
173. Beavers, L.S., Finley, D.R., Gadski, R.A. et al. 2006. WO2006101808A1.
174. Beavers, L.S., Finley, D.R., Finn, T.P. et al. 2005. WO2005097740A1.
175. Beavers, L.S., Gadski, R.A., Jesudason, C.D. et al. 2005. WO2005121080A1.
176. Finley, D.R., Finn, T.P., Hipskind, P.A. et al. 2006. WO2006023462A1.
177. Hipskind, P.A., Takakuwa, T., Jesudason, C.D. et al. 2006. WO2006107661A1.
178. Jesudason, C.D., Beavers, L.S., and Cramer, J.W. 2006. (3-Piperidin-1-ylpropoxy)- tetrahydroisoquinolines and tetra-hydroazepines: A novel series of selective histamine H3 receptor antagonists. 35th Eur. Histamine Res. Soc. Meeting, Delphi, Greece, Abst. P11.
179. Gadski, R.A., Hipskind, P.A., Jesudason, C.D. et al. 2004. WO2004018432A1.
180. Beavers, L.S., Finley, D.R., Gadski, R.A. et al. 2004. WO2004026837A2.
181. Poissonnet, G., Parmentier, J.-G., and Boutin, J.A. 2006. Rational exploration of structural databases: The case of H3 ligands. Abstr. 1st Coast to Coast Medicinal and Synthetic Chemistry Symposium, Torquay, U.K.
182. Goldstein, S., Poissonnet, G., Parmentier, J-G. et al. 2003. EP1275647A1.
183. Desos, P., Cordi, A. and Lestage, P. 2006. WO2006120348A1.
184. Casara, P., Chollet, A.M., Dhainaut, A. et al. 2005. FR2866647A1.
185. Freichel, C., Arthur, S.G., and Hertel, C. 2006. Histamine 3 receptor inverse agonists for the treatment of obesity. Biological and chemical challenges. 35th Eur. Histamine Res. Soc. Meeting, Delphi, Greece, Abst. P8.
186. Mcarthur, S.G., Hertel, C., Nettekoven, M.H. et al. 2005. WO2005117865A1.
187. McArthur, S.G., Hertel, C., Nettekoven, M.H. et al. 2006. US2006084679A1.
188. Nettekoven, M.H., Plancher, J-M., Roche, O. et al. 2006. US2006160855A1.
189. Nettekoven, M.H., Plancher, J-M., Richter, H. et al. 2007. WO2007065820A1.
190. Richter, H.G.F., Adams, D.R., Benardeau, A. et al. 2006. Synthesis and biological evaluation of novel hexahydro-pyrido[3',2': 4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT2C receptor agonists. Bioorg. Med. Chem. Lett. 16: 1207-1211.
191. Nettekoven, M. and Roche, O. 2007. WO2007068641A1.
192. Bernardelli, P., Cronin, A.M., Denis, A. et al. 2005. WO2005108384A1.
193. Wlodecki, B. 2006. US2006047114A1.
194. Howard, H.R. and Wlodecki, B. 2005. US2005282811A1.
195. Wager, T.T. and Chandrasekaran, R.Y. 2005. US2005171181A1.
196. Howard, H.R. and Wlodecki, B. 2005. US2005245543A1.
197. Wager, T.T. and Chandrasekaran, R.Y. 2005. US2005171181A1.
198. Strang, R.S., Lunn, G. and Mathias, J.P. 2005. EP1595881A1.
199. Mizutani, T., Nagase, T., Sato, N. et al. 2005. WO2005115993A1.
200. Takahashi, T., Kanatani, A., Tokita, S. et al. 2005. WO2005077953A1.
201. Jitsuoka, M., Sato, N., Tsukahara, D. et al. 2006. WO2006028239A1.
202. Bennani, Y., Anderson, J.T., Wang, J. et al. 2006. WO2006071750A1.
203. Folmer, J., Hunt, S.F., Hamley, P. et al. 2006. WO2006014135A1.
204. Folmer, J., Hunt, S.F., Hamley, P. et al. 2006. WO2006014136A1.
205. Diaz Martin, J.A. and Jimenez Bargueno, M.D. 2005. WO2005118547A1.
206. Diaz Martin, J.A., Escribano Arenales, B. and Martin Escudero Perez, U. 2005. WO2005037810A2.
207. Pringle, W.C., Peterson, J.M., Xie, L. et al. 2006. WO2006089076A2.
208. Xie, L., Ochterski, J.W., Gao, Y. et al. 2007. WO2007016496A2.
209. Aslanian, R., Zhu, X., Tom, W. et al. 2006. Benzimidazole-substituted (3-phenoxypropyl) amines as histamine H3 receptor ligands. 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006. Abst. MEDI-501.
210. Aslanian, R.G., Tom, W.C. and Zhu, X. 2006. WO2006078775A1.
211. Aslanian, R.G., Berlin, M.Y., Mangiaracina, P. et al. 2004. WO2004000831A1.
212. Ting, P.C., Aslanian, R.G., Berlin, M.Y. et al. 2004. WO2003103669A1.
213. Celanire, S. and Denonne, F. 2006. WO2006103045A1.
214. Celanire, S., Talaga, P., Leurs, R. et al. 2006. WO2006103057A1.
215. Santora, V.J., Covel, J.A., Hayashi, R. et al. 2007. WO2007061741A2.
216. De Esch, I.J.P., Mills, J.E.J., Perkins, T.D.J. et al. 2001. Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE. J. Med. Chem. 44: 1666-1674.
217. De Esch, I.J.P., Timmerman, H., Menge, W.M.P.B. et al. 2000. A qualitative model for the histamine H3 receptor explaining agonistic and antagonistic activity simultaneously. Archiv der Pharmazie (Weinheim, Germany) 333: 254-260.
218. Ter Laak, A.M., Timmerman, H., Leurs, R. et al. 1995. Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-agonists: Asp116 (TM3) has a constitutive role in receptor stimulation. J. Comp.-Aided Mol. Design 9: 319-330.
219. Windhorst, A.D., Timmerman, H., Worthington, E.A. et al. 2000. Characterization of the binding site of the histamine H3 Receptor. 2. Synthesis, in vitro pharmacology, and QSAR of a series of monosubstituted benzyl analogues of thioperamide. J. Med. Chem. 43: 1754-1761.
220. Lorenzi, S., Mor, M., Bordi, F. et al. 2005. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Bioorg. Med. Chem. 13: 5647-5657.
221. Uveges, A.J., Kowal, D., Zhang, Y. et al. 2002. The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J. Pharmacol. Exp. Ther. 301: 451-458.
222. Moguilevsky, N., Varsalona, F., Guillaume, J.P. et al. 1995. Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H1 histamine receptor stably expressed in CHO cells. J Recept. Signal Transduct. Res 15: 91-102.
223. Leurs, R., Smit, M.J., Tensen, C.P. et al. 1994. Site-directed mutagenesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. Biochem. Biophys. Res. Commun. 201: 295-301.
224. Gantz, I., DelValle, J., Wang, L.D. et al. 1992. Molecular basis for the interaction of histamine with the histamine H2 receptor. J. Biol. Chem. 267: 20840-20843.
225. Shin, N., Coates, E., Murgolo, N.J. et al. 2002. Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mol. Pharmacol. 62: 38-47.
226. Visiers, I., Ballesteros, J.A., and Weinstein, H. 2002. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol. 343: 329-371.
227. Morini, G., Comini, M., Rivara, M. et al. 2006. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold. Bioorg. Med. Chem. Lett. 16: 4063-4067.
228. Stark, H., Sippl, W., Ligneau, X. et al. 2001. Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg. Med. Chem. Lett. 11: 951-954.
229. Ligneau, X., Morisset, S., Tardivel-Lacombe, J. et al. 2000. Distinct pharmacology of rat and human histamine H3 receptors: Role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. 131: 1247-1250.
230. Yao, B.B., Hutchins, C.W., Carr, T.L. et al. 2003. Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity. Neuropharmacol. 44: 773-786.
231. Boeckler, F., Lanig, H., and Gmeiner, P. 2005. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. J. Med. Chem. 48: 694-709.
232. Bockaert, J. and Pin, J.P. 1999. Molecular tinkering of G protein-coupled receptors: An evolutionary success. EMBO J. 18: 1723-1729.
233. Fahmy, K., Jager, F., Beck, M. et al. 1993. Protonation states of membrane- embedded carboxylic acid groups in rhodopsin and metarhodopsin II: A Fourier-transform infrared spectroscopy study of site-directed mutants. Proc. Natl Acad. Sci. U.S.A. 90: 10206-10210.
234. Okada, T., Fujiyoshi, Y., Silow, M. et al. 2002. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl Acad. Sci. U.S.A. 99: 5982-5987.
235. Axe, F.U., Bembenek, S.D., and Szalma, S. 2006. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. J. Mol. Graph. Model. 24: 456-464.
236. Schlegel, B. 2005. The human histamine H3-receptor: A molecular modelling study of a G-protein coupled receptor. Dissertation, Cuvillier Verlag, Göttingen, September 25.
237. Schlegel, B., Stark, H., Sippl, W. et al. 2005. Model of a specific human histamine H3 receptor (hH3R) binding pocket suitable for virtual drug design. Inflamm. Res. 54: S50-S51.
238. Narkhede, S.S. and Degani, M.S. 2007. Pharmacophore refinement and 3D-QSAR studies of histamine H3 antagonists. QSAR Combi. Sci. 26: 744-753.
239. Jansen, F.P., Leurs, R., and Timmerman, H. 1998. Synthesis of radioligands for the histamine H3 receptor. In: The Histamine H3 Receptor: A Target for New Drugs. Eds R. Leurs, H. Timmerman, Elsevier, Amsterdam: pp. 127-144.
240. Windhorst, A.D., Leurs, R., Menge, W.M. et al. 1998. Synthesis of radioligands for the histamine H3 receptor. In: The Histamine H3 Receptor: A Target for New Drugs. Eds R. Leurs, H. Timmerman, Elsevier, Amsterdam: pp. 139-174.
241. Esbenshade, T.A., Yao, B.B., Witte, D.G. et al. 2005. Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology. Inflamm. Res. 54: S46-S47.
242. Yao, B.B., Witte, D.G., Miller, T.R. et al. 2006. Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor. Neuropharmacology 50: 468-478.
243. Witte, D.G., Yao, B.B., Miller, T.R. et al. 2006. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand. Br. J. Pharmacol. 148: 657-670.
244. Barbier, A.J., Berridge, C., Dugovic, C. et al. 2004. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br. J. Pharmacol. 143: 649-661.
245. Airaksinen, A.J., Jablonowski, J.A., van der, M.M. et al. 2006. Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: Evaluation of a potential PET ligand. Nucl. Med. Biol. 33: 801-810.
246. Plisson, C. 2006. WO2006072596A1.
247. Cowart, M., Gfesser, G.A., Bhatia, K. et al. 2006. Fluorescent benzofuran histamine H3 receptor antagonists with sub-nanomolar potency. Inflamm. Res. 55: S47-S48.
248. Amon, M., Ligneau, X., Camelin, J.C. et al. 2007. Highly potent fluorescence-tagged nonimidazole histamine H3 receptor ligands. Chem. Med. Chem. 2: 708-716.
249. Keith, C.T., Borisy, A.A., and Stockwell, B.R. 2005. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Disc. 4: 71-78.
250. Zimmermann, G.R., Lehar, J., and Keith, C.T. 2007. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Disc. Today 12: 34-42.
251. Nakaya, M., Fukushima, Y., Takeuchi, N. et al. 2005. Nasal allergic response mediated by histamine H3 receptors in murine allergic rhinitis. Laryngoscope 115: 1778-1784.
252. McLeod, R.L., Mingo, G.G., Kreutner, W. et al. 2005. Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. Life Sci. 76: 1787-1794.
253. McLeod, R.L., Rizzo, C.A., West, R.E., Jr. et al. 2003. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N’-[[4-(1H-imidazol-4-ylmethyl)phenyl]methyl]urea (SCH 79687). J. Pharmacol. Exp. Ther. 305: 1037-1044.
254. Taylor-Clark, T. and Foreman, J. 2005. Histamine-mediated mechanisms in the human nasal airway. Curr. Opin. Pharmacol. 5: 214-220.
255. Fonquerna, S. and Miralpeix, M. 2006. H1 antihistamines: Patent highlights 2000-2005. Expert Opin. Ther. Pat. 16: 109-117.
256. Anthes, J.C., West, R.E., Hey, J.A. et al. 2004. WO2004066960A2.
257. Cremers, T.IF.H. and Hogg Willigers, S. 2005. WO2005056056A2.
258. Schwartz, J. and Lecomte, J. 2005. WO2005000315A1.
259. Morphy, R., Kay, C., and Rankovic, Z. 2004. From magic bullets to designed multiple ligands. Drug Disc. Today 9: 641-651.
260. Huls, A., Purand, K., Stark, H. et al. 1996. Diphenylmethyl ethers: Synthesis and histamine H3-receptor antagonist in vitro and in vivo activity. Bioorg. Med. Chem. Lett. 6: 2013-2018.
261. Aslanian, R., Mutahi, M.W., Shih, N.Y. et al. 2002. Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template. Bioorg. Med. Chem. Lett. 12: 937-941.
262. Shih, N-Y., Aslanian, R.G., Solomon, D.M. et al. 2002. WO200244141A2.
263. Isensee, K., Amon, M., and Sasse, B. 2007. Novel potent dual histamine H1/H3 receptor antagonists. 36th European Histamine Research Society Meeting, May 9-12 2007, Florence, Italy. Abst. P33.
264. Tosco, P., Bertinaria, M., Di Stilo, A. et al. 2004. A new class of NO-donor H3-antagonists. Farmaco 59: 359-371.
265. Tosco, P., Bertinaria, M., Di Stilo, A. et al. 2005. Non-imidazole histamine NO-donor H3-antagonists. Farmaco 60: 507-512.
266. Tosco, P., Bertinaria, M., Di Stilo, A. et al. 2005. Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. Bioorg. Med. Chem. 13: 4750-4759.
267. Decker, M. 2007. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini-Rev. Med. Chem. 7: 221-229.
268. Muñoz-Torrero, D. and Camps, P. 2006. Dimeric and hybrid anti-alzheimer drug candidates. Curr. Med. Chem. 13: 399-422.
269. Apelt, J., Ligneau, X., Pertz, H.H. et al. 2002. Development of a new class of nonimidazole histamine H3 receptor ligands with combined inhibitory histamine N-methyltransferase activity. J. Med. Chem. 45: 1128-1141.
270. Apelt, J., Grassmann, S., Ligneau, X. et al. 2005. Search for histamine H3 receptor antagonists with combined inhibitory potency at Nt-methyltransferase: Ether derivatives. Pharmazie 60: 97-106.
271. Grassmann, S., Apelt, J., Sippl, W. et al. 2003. Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine H3 receptor affinities. Bioorg. Med. Chem. 11: 2163-2174.
272. Grassmann, S., Apelt, J., Ligneau, X. et al. 2004. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: Omegapiperidinoalkanamine derivatives. Arch. Pharm. (Weinheim) 337: 533-545.
273. Petroianu, G., Arafat, K., Sasse, B.C. et al. 2006. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie 61: 179-182.
274. Horton, J.R., Sawada, K., Nishibori, M. et al. 2005. Structural basis for inhibition of histamine N-methyltransferase by diverse drugs. J. Mol. Biol. 353: 334-344.
275. Vohora, D., Pal, S.N., and Pillai, K.K. 2005. Modulation of spontaneous alternation performance of mice treated with thioperamide and tacrine in a cross maze task. Fundam. Clin. Pharmacol. 19: 531-532.
276. Hey, J.A. and Aslanian, R.G. 2002. WO2002072093A2.
277. Gray, J.A. and Roth, B.L. 2006. Developing selectively nonselective drugs for treating CNS disorders. Drug Discov. Today Ther. Strat. 3: 413-419.
278. Keith, J.M., Gomez, L.A., Letavic, M.A. et al. 2007. Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore. Bioorg. Med. Chem. Lett. 17: 702-706.
279. Letavic, M.A., Keith, J.M., Jablonowski, J.A. et al. 2007. Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 17: 1047-1051.
280. Keith, J.M., Gomez, L.A., Wolin, R.L. et al. 2007. Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett. 17: 2603-2607.
281. Letavic, M.A., Keith, J.M., Ly, K.S. et al. 2007. Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors. Bioorg. Med. Chem. Lett. 17: 2566-2569.
282. 3 receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol. Dis. 30(1): 74-83.
283. JP Morgan 24th Annual Healthcare Conference, San Francisco, CA, January 2006, Cephalon website, www.cephalon.com.
284. Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, February 2007, Cephalon website, www.cephalon.com.
285. Hunter, J. Neurology, GlaxoSmithKline website, http://www.gsk.com/investors/presen tations_webcasts04.htm.
286. Ratti, E. Psychiatry, GlaxoSmithKline website, http://www.gsk.com/investors/presen tations_webcasts04.htm.
287. http://www.schizophreniaforum.org/res/trials/all.pdf.
288. Effectiveness of the drug GSK189254 in treating patients with narcolepsy, http://clinicaltrials.gov/show/NCT00366080.
289. A study of GSK189254 and duloxetine in the electrical hyperalgesia model of healthy volunteers, http://clinicaltrials.gov/show/NCT00387413.
290. An imaging study to investigate the distribution of GSK239512 in the brain, http://clinicaltrials.gov/show/NCT00474513.
291. Effects of single doses of GW784568X on allergic rhinitis symptoms in male subjects whilst in an environmental chamber, http://clinicaltrials.gov/show/NCT00404586.
292. Norman, P. 2007. A H3 antagonist for treating allergic rhinitis: A development candidate? Expert Opin. Ther. Pat. 17: 449-452.
293. McLeod, R.L., Mingo, G.G., Herczku, C. et al. 1999. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am. J. Rhinol. 13: 391-399.
294. http://www.stanleyresearch.org/Trial/Drug/AwardedTrial.aspx.
295. http://www.schizophreniaforum.org/res/trials/all.pdf.
296. Schwartz, J., Lecomte, J., Raga, M., Sallares, J., Guerrero, M. et al. 2006. WO2006103546A2.
297. Raga, M.M. et al. 2006. WO2006084833A1.
298. Schwartz, J. and Lecomte, J. 2006. WO2006103537A2.
299. Sanofi-Aventis website, http://www.sanofi-aventis.com/rd/portfolio/p_rd_portfolio_ snc.asp.
300. Dastmalchi, S., Hamzeh-Mivehroud, M., Ghafourian, T. et al. 2007. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists. J. Mol. Graph. Model. 26(5): 834-844.
301. Roche, O. and Rodriguez Sarmiento, R.M. 2007. A new class of histamine H3 receptor antagonists derived from ligand based design. Bioorg. Med. Chem. Lett. 17: 3670-3675.
302. Del Tredici, A.L., Eskildsen, J., Andersen, C.B. et al. 2007. Identification of histamine H3 receptor antagonists. FASEB J. 21: A790-A79d.
303. DiModica, L. 2004. Fixed-combination therapies for the treatment of CNS disorders. Analysis of current trends and future prospects among U.S. physicians and HMOs. Decision Resour. November 2004.
304. Mierzwa, R., King, A., Conover, M.A. et al. 1994. Verongamine, a novel bromotyrosinederived histamine H3-antagonist from the marine sponge Verongula gigantean. J. Nat. Prod. 57: 175-177.